384P - Choice of Adjuvant Therapy in Uveal Melanoma: A Retrospective Analysis in China (384P)

Date 18 November 2017
Event ESMO Asia 2017 Congress
Session Poster lunch
Topics Anti-Cancer Agents & Biologic Therapy
Melanoma and other Skin Tumours
Presenter Lili Mao
Citation Annals of Oncology (2017) 28 (suppl_10): x113-x116. 10.1093/annonc/mdx667
Authors L. Mao, L. Si, X. Bai, Z. Chi, C. Cui, X. Sheng, B. Lian, T. Bixia, X. Yan, J. Guo
  • Department Of Renal Cell Carcinoma & Melanoma, Peking University Cancer Hospital-Beijing Cancer Hospital, 100142 - Beijing/CN



Despite effective local tumor control with radioactive plaque brachytherapy, endoresection, or enucleation, many UM (uveal melanoma) patients ultimately developed fatal metastases. This study aims to evaluate the adjuvant treatment of UM patients after surgery.


Between March 2008 and Jan 2016, consecutively admitted uveal melanoma patients to Renal & melanoma department at the Beijing Cancer Hospital, were included in this cohort study. Choice of adjuvant therapy, recurrence-free survival and first metastatic sites, were analysed retrospectively.


In total, 97 uveal melanoma patients were investigated retrospectively. From this 97 pts, 57 were male, 47 pts had primary lesions in their left eyes, median age 46 year-old (20-72yrs). Most pts had UM arising from the choroid (97%). Seven pts were stage IV when first diagnosed. The rest 90 pts receive enucleation (61/90), endoresection (8/90), bradytherapy (21/90) respectively after initial uveal melanoma detection. Sixty-nine pts who received radical surgery of UM were divided in to observation group (n = 39), interferon group (n = 15), chemo group (n = 13), dendritic cell vaccination group (n = 2) with respect of post-surgery treatment. Of 69 pts, 57 had developed metastasis. Median replase-free survival was 2.6 years in observation group and 4.6 years in the chemo group (P 5×ULN).


Adjuvant chemotherapy or interferon might be reasonable options for patients with UM melanoma after surgery. We need more potent adjuvant therapy for this long term dormant but fatal disease.

Clinical trial identification

Legal entity responsible for the study

Beijing Cancer Hospital


(Supported by the National Natural Science Foundation of China (81301984), Beijing Nova Program (XX2013027) and Program for New Century Excellent Talents in University (NCET-13-0007).


All authors have declared no conflicts of interest.